Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy

被引：31

作者：

Hessel F.P. ^{[1
,5
]}

Wegner C. ^{[2
]}

Müller J. ^{[3
]}

Glaveris C. ^{[4
]}

Wasem J. ^{[1
]}

机构：

[1] University of Duisburg-Essen, Essen

[2] German Heart Institute, Berlin

[3] Clinic for Internal Medicine, Offenbach

[4] Institute for Health Care Management, Faculty of Economics, University of Duisburg-Essen, 45117 Essen

来源：

The European Journal of Health Economics, formerly: HEPAC | 2004年 / 5卷 / 1期

关键词：

Autoantibodies; Cardiomyopathy; Cost-effectiveness; Survival;

D O I：

10.1007/s10198-003-0202-5

中图分类号：

学科分类号：

摘要：

Idiopathic dilated cardiomyopathy (DCM) is a life-threatening heart disease and a major reason for heart transplantations. The medical efficacy of immunoadsorption (IA) for DCM patients has been demonstrated in initial clinical studies. This prospective matched-case control study examined 5-year survival rates, direct medical costs, and cost-effectiveness in Germany (n=34) from a health-care system perspective. In a cost-effectiveness analysis costs per life year gained were calculated. Patients treated with IA showed a greater survival rate: 5-year survival rate in the intervention group was 82% vs. 41% in controls. Log rank statistics after Kaplan-Meier analysis of cumulated survival probability were highly significant. Initial intervention costs for IA were found to be € 28,400 per patient treated. Direct medical costs for a 5-year follow-up were € 128,600 per patient treated with IA and € 75,500 in controls. Considering only the actual survival time we calculated annual treatment costs of € 24,900 in the IA group and € 28,900 in controls. The cost-effectiveness ratio expressed in costs per life year gained was € 34,400. This is the first controlled study to perform 5-year survival analysis and economic evaluation of this new emerging technology for patients with DCM. Although high initial treatment costs for IA are incurred, the significantly better survival rates lead to reasonable costs per live year gained.

引用

页码：58 / 63

页数：5

共 19 条

[1]

Bland J.M., Altman D.G., Survival probabilities (the Kaplan-Meier method), BMJ, 317, (1998)

[2]

A Guidance Document for the Costing Process, (1996)

[3]

Guidelines for Economic Evaluation of Pharmaceuticals: Canada, 2nd Edn., (1997)

[4]

Dec G.W., Fuster V., Idiopathic dilated cardiomyopathy - Review article, N Engl J Med, 331, pp. 1564-1575, (1994)

[5]

Drummond M.F., O'Brien B.J., Stoddart G.L., Torrance G.W., Methods for the Economic Evaluation of Health Care Programmes, (1997)

[6]

Feldman A.M., McNamara D.M., Myocarditis, N Engl J Med, 343, pp. 1388-1398, (2000)

[7]

Felix S.B., Staudt A., Dorffel W.V., Stangl V., Merkel K., Pohl M., Docke W.D., Morgera S., Neumayer H.H., Wernecke K.D., Wallukat G., Stangl K., Baumann G., Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: Three-month results from a randomized study, J Am Coll Cardiol, 35, pp. 1590-1598, (2000)

[8]

Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C., Cost-effectiveness in Health and Medicine, (1996)

[9]

Gruppe H.K., Empfehlungen zur gesundheitsökonomischen Evaluation - Revidierte Fassung des Hannoveraner Konsens, Gesundheitsokon Qualitats-Manage, 4, (1999)

[10]

Hessel F.P., Kohlmann T., Krauth C., Nowy R., Seitz R., Siebert U., Wasem J., Ökonomische Evaluation in der Rehabiliation: Prinzipien und Empfehlungen für die Leistungseffassung, DRV-Schriften, 16, pp. 103-246, (1999)

← 1 2 →